Background: Anticancer therapies are associated with significant adverse side effects and few treatments that alleviate symptoms exist. Branched-chain amino acids (BCAAs) have been investigated as an intervention for reducing anticancer therapy side effects, although a review of the literature results has yet to be published. Aim: The current review summarizes evidence surrounding this topic and suggests both support and caution in using BCAAs as a treatment for patients receiving anticancer therapies. Methods: In this review, two literature searches were completed. Google Scholar, PubMed, EBSCOhost, and Cochrane databases were searched using the terms “branched-chain amino acids and cancer” and “BCAA and cancer.” Results: Two bodies of evidence emerged: One supporting beneficial effects and the other showing adverse outcomes of BCAA supplementation in patients with cancer. Evidence of benefit was a decrease in malnourishment and unintentional weight loss during and after chemotherapy. Potential harms included the idea cancer cells may utilize BCAAs as a source of energy for growth. Conclusions: Supplementation of BCAAs in individuals with cancer should be implemented cautiously. Those who are severely malnourished due to anticancer therapy may benefit the most. BCAA supplementation may also be provided once cancer has been destroyed from the individual's body to aid with recovery.
DeutzNEP, et al. (2011) Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food. Clinical Nutrition30(6): 759–768.
7.
EguchiY, et al. (2017) ‘Weariness’ and ‘unpleasantness’ reduce adherence to branched-chain amino acid granules among Japanese patients with liver cirrhosis: Results of a single-center cross-sectional survey. Hepatology Research47(3): E169–E177.
8.
EricksenRE, et al. (2019) Loss of BCAA catabolism during carcinogenesis enhances mtorc1 activity and promotes tumor development and progression. Cell Metabolism29(5): 1151–1165.e6.
9.
HachiyaH, et al. (2020) Effects of branched-chain amino acids on postoperative tumor recurrence in patients undergoing curative resection for hepatocellular carcinoma: A randomized clinical trial. Journal of Hepato-Biliary-Pancreatic Sciences27(11): 819–829.
10.
HassanAA, et al. (2015) SA1840 Effects of oral l-carnitine on liver functions after transarterial chemoembolization (TACE) in intermediate stage hepatocellular carcinoma (HCC) patients. Gastroenterology148(4): S-1021.
11.
Information and resources about cancer (2022) American Cancer Society. Available at: https://www.cancer.org/ (Accessed: November 4, 2021).
12.
KatagiriR, et al. (2020) Dietary intake of branched-chain amino acids and risk of colorectal cancer. Cancer Prevention Research13(1): 65–72.
13.
KikuchiY, et al. (2016) A randomized clinical trial of preoperative administration of branched-chain amino acids to prevent postoperative ascites in patients with liver resection for hepatocellular carcinoma. Annals of Surgical Oncology23(11): 3727–3735.
14.
LeiM-Z, et al. (2020) Acetylation promotes BCAT2 degradation to suppress BCAA catabolism and pancreatic cancer growth. Signal Transduction and Targeted Therapy5(1): 70. DOI: https://doi.org/10.1038/s41392-020-0168-0.
15.
LieuEL, et al. (2020) Amino acids in cancer. Experimental & Molecular Medicine52(1): 15–30.
16.
MoriharaD, et al. (2012) Late-evening snack with branched-chain amino acids improves liver function after radiofrequency ablation for hepatocellular carcinoma. Hepatology Research42(7): 658–667.
17.
NojiriS, et al. (2017) Effects of branched-chain amino acid supplementation after radiofrequency ablation for hepatocellular carcinoma: A randomized trial. Nutrition (Burbank, Los Angeles County, Calif.)33: 20–27.
18.
PengH, et al. (2020) Multifaceted role of branched-chain amino acid metabolism in cancer. Oncogene39(44): 6747–6756.
19.
SeebacherNA, et al. (2019) Clinical development of targeted and immune based anti-cancer therapies. Journal of Experimental & Clinical Cancer Research38(1). Available at:https://doi.org/10.1186/s13046-019-1094-2.
20.
SimundićAM (2013) Bias in research. Biochemia medica23(1): 12–15.
21.
SivanandSVander HeidenMG (2020) Emerging roles for branched-chain amino acid metabolism in cancer. Cancer Cell37(2): 147–156.
22.
StorckLJ, et al. (2020) Effect of a leucine-rich supplement in combination with nutrition and physical exercise in advanced cancer patients: A randomized controlled intervention trial. Clinical Nutrition39(12): 3637–3644.
23.
TadaT, et al. (2015) Impact of branched-chain amino acid granule therapy in patients with hepatocellular carcinoma who have normal albumin levels and low branched-chain amino acid to tyrosine ratios. Nutrition and Cancer71(7): 1132–1141.
24.
TaherizadehM, et al. (2021) Plasma changes of branched-chain amino acid in patients with esophageal cancer. Middle East Journal of Digestive Diseases13(1): 49–53.
25.
WangP, et al. (2018) BCAT1 promotes proliferation of endometrial cancer cells through reprogrammed BCAA metabolism. Int J Clin Exp Pathol [Preprint]11(12): 5536–5546.
26.
YoshijiH, et al. (2013) Branched-chain amino acids suppress the cumulative recurrence of hepatocellular carcinoma under conditions of insulin-resistance. Oncology Reports30(2): 545–552.
27.
ZaborE, et al. (2020) Randomized controlled trials. Chest158(1S): S79–S87.
